HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kipriyanov, S. M. Articles by Little, M. Search for Related Content PubMed PubMed Citation Articles by Kipriyanov, S. M. Articles by Little, M.

Synergistic Antitumor Effect of Bispecific CD19 x CD3 and CD19 x CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma¹

Sergey M. Kipriyanov^2,3,*, Björn Cochlovius^2,, Holger J. Schäfer^2,*, Gerhard Moldenhauer, Alexandra Bähre, Fabrice Le Gall^*, Stefan Knackmuss^* and Melvyn Little^*

^* Affimed Therapeutics, Heidelberg, Germany; and Recombinant Ab Research Group and Department of Molecular Immunology, German Cancer Research Center, Heidelberg, Germany

To target NK cells against non-Hodgkin’s lymphoma, we constructed a bispecific diabody (BsDb) with reactivity against both human CD19 and FcRIII (CD16). Bacterially produced CD19 x CD16 BsDb specifically interacted with both CD19⁺ and CD16⁺ cells and exhibited significantly higher apparent affinity and slower dissociation from the tumor cells than from effector cells. It was able to induce specific lysis of tumor cells in the presence of isolated human NK cells or nonfractionated PBLs. The combination of the CD19 x CD16 BsDb with a previously described CD19 x CD3 BsDb and CD28 costimulation significantly increased the lytic potential of human PBLs. Treatment of SCID mice bearing an established Burkitt’s lymphoma (5 mm in diameter) with human PBLs, CD19 x CD16 BsDb, CD19 x CD3 BsDb, and anti-CD28 mAb resulted in the complete elimination of tumors in 80% of animals. In contrast, mice receiving human PBLs in combination with either diabody alone showed only partial tumor regression. These data clearly demonstrate the synergistic effect of small recombinant bispecific molecules recruiting different populations of human effector cells to the same tumor target.

This article has been cited by other articles:

				R. Stork, D. Muller, and R. E. Kontermann A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G Protein Eng. Des. Sel., November 3, 2007; (2007) gzm061v1. [Abstract] [Full Text] [PDF]

				C.-Y. Xiong, A. Natarajan, X.-B. Shi, G. L. Denardo, and S. J. Denardo Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding Protein Eng. Des. Sel., August 1, 2006; 19(8): 359 - 367. [Abstract] [Full Text] [PDF]

				J. Shen, M. D. Vil, X. Jimenez, M. Iacolina, H. Zhang, and Z. Zhu Single Variable Domain-IgG Fusion: A NOVEL RECOMBINANT APPROACH TO Fc DOMAIN-CONTAINING BISPECIFIC ANTIBODIES J. Biol. Chem., April 21, 2006; 281(16): 10706 - 10714. [Abstract] [Full Text] [PDF]

				T. Dreier, P. A. Baeuerle, I. Fichtner, M. Grun, B. Schlereth, G. Lorenczewski, P. Kufer, R. Lutterbuse, G. Riethmuller, P. Gjorstrup, et al. T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct J. Immunol., April 15, 2003; 170(8): 4397 - 4402. [Abstract] [Full Text] [PDF]

				L. J. N. Cooper, M. S. Topp, L. M. Serrano, S. Gonzalez, W.-C. Chang, A. Naranjo, C. Wright, L. Popplewell, A. Raubitschek, S. J. Forman, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect Blood, February 15, 2003; 101(4): 1637 - 1644. [Abstract] [Full Text] [PDF]